{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-024134","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.579495+00:00","generated_at":"2026-06-13T10:35:40.614696+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Evofem raises $965k net via $1.5M convertible note and warrant offering","bullets":["Issued $1.5M principal of senior subordinated convertible notes with 8% interest (12% default); convertible at $1.25/share.","Investors paid ~$650 per $1,000 principal (65% of face); net proceeds ~$965k after expenses.","Warrants to purchase 1.2M shares at $1.25/share, exercisable for 5 years with cashless exercise and price adjustment.","Notes mature March 6, 2026; change of control redemption at 125% premium; beneficial ownership capped at 4.99%.","Registration rights agreement requires S-1 filing within 90 days; 2% monthly penalty for filing/effectiveness failure."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-024134","json":"https://secwatch.observer/filing/0001493152-23-024134.json","markdown":"https://secwatch.observer/filing/0001493152-23-024134.md","text":"https://secwatch.observer/filing/0001493152-23-024134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223024134/0001493152-23-024134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223024134/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:35:40.614696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b777b90dc6ee735c226b3a9152d3d57734bda8f5","claim":"Evofem Biosciences, Inc. entered into Securities Purchase Agreement with certain investors valued at $1,500,000 (effective 2023-07-03).","evidence_excerpt":"On July 3, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (“ SPA ”) with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $1,500,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223024134/0001493152-23-024134-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"$1,500,000"},{"label":"Effective","value":"2023-07-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}